GH Research (NASDAQ:GHRS) Stock Rating Cut to “Sell” at Wall Street Zen

Wall Street Zen downgraded shares of GH Research (NASDAQ:GHRS) from a hold rating to a sell rating in a research note issued to investors on Saturday,Wall Street Zen reports.

Several other research firms have also issued reports on GHRS. Zacks Research upgraded shares of GH Research from a “strong sell” rating to a “hold” rating in a report on Thursday, August 13th. Needham & Company LLC upped their price objective on shares of GH Research from $32.00 to $39.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of GH Research in a research report on Thursday, October 15th. Wells Fargo & Company started coverage on shares of GH Research in a research report on Monday, July 27th. They set an “overweight” rating and a $44.00 price objective for the company. Finally, Cantor Fitzgerald lifted their target price on shares of GH Research from $35.00 to $40.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $45.00.

GH Research Stock Down 2.3%

NASDAQ GHRS opened at $18.07 on Friday. The company has a market capitalization of $1.24 billion, a price-to-earnings ratio of -18.07 and a beta of 1.32. GH Research has a twelve month low of $12.04 and a twelve month high of $31.44. The stock has a fifty day simple moving average of $24.94 and a 200 day simple moving average of $24.04.

GH Research (NASDAQ:GHRS) last announced its earnings results on Thursday, August 6th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.06. Research analysts expect that GH Research will post -1.20 earnings per share for the current fiscal year.

Institutional Trading of GH Research

Several hedge funds have recently modified their holdings of GHRS. Troluce Capital Advisors LLC grew its holdings in GH Research by 165.4% during the 1st quarter. Troluce Capital Advisors LLC now owns 990,472 shares of the company’s stock valued at $13,926,000 after buying an additional 617,260 shares in the last quarter. Braidwell LP bought a new stake in shares of GH Research during the second quarter valued at about $5,571,000. Renaissance Technologies LLC purchased a new stake in shares of GH Research in the first quarter worth about $290,000. Squarepoint Ops LLC purchased a new stake in shares of GH Research in the second quarter worth about $495,000. Finally, Farther Finance Advisors LLC lifted its holdings in shares of GH Research by 9,720.0% in the third quarter. Farther Finance Advisors LLC now owns 9,820 shares of the company’s stock worth $231,000 after buying an additional 9,720 shares in the last quarter. Institutional investors own 56.90% of the company’s stock.

GH Research Company Profile

GH Research plc is a clinical-stage biopharmaceutical company focused on developing novel therapies for psychiatric and neurological disorders. The company is headquartered in Dublin, Ireland, and conducts research and clinical development activities through its proprietary pipeline of psychedelic-based medicines.

Its lead program, GH001, is an investigational inhaled formulation of mebufotenin, also known as 5-MeO-DMT. GH Research has studied GH001 in patients with treatment-resistant depression, with the aim of developing a rapidly acting treatment that may provide meaningful improvements following a short course of administration.